Abstracts tagged "corticosteroids"

Abstract Number: 028 • 2023 Pediatric Rheumatology Symposium
Achieving Medication-Free Remission in Juvenile Dermatomyositis
Harneet Ghumman¹, Ilaria Maccora², Hermine Brunner¹, Amy Cassedy³, Mekibib Altaye², Asra Firdous¹, Alexei Grom¹, Daniel Lovell¹, Angela Merritt¹, Megan Quinlan-Waters¹ and Sheila Angeles-Han², ¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Cincinnati Children's Hospital, Cincinnati, OH, ³Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: Juvenile dermatomyositis (JDM) is characterized by symmetric proximal muscle weakness, distinct rash, and a risk for calcinosis. Systemic immunosuppression is needed. Evidence is limited…
Abstract Number: L17 • ACR Convergence 2022
Evaluating the Safety and Factors Associated with Treatment Cessation in Takayasu Arteritis
Robert Maughan¹, Andrew Porter¹, Chanaka Dahanayake², Claudia Ianonne¹, Ritu Alapat¹, Charis Pericleous¹, Taryn Youngstein³ and Justin Mason¹, ¹Imperial College London, London, United Kingdom, ²Barts Health NHS Trust, London, United Kingdom, ³Imperial NHS Trust, London, United Kingdom
Background/Purpose: Immunosuppression in Takayasu Arteritis (TA) reduces the risk of arterial damage and disease progression. However, long-term use of glucocorticoids (GC) and other immunosuppressants carries…
Abstract Number: 0866 • ACR Convergence 2022
Outcomes of Children with Uveitis Associated with Autosomal Dominant Neovascular Inflammatory Vitreoretinopathy (ADNIV) Treated with Methotrexate and Infliximab
Sheila Angeles-Han¹, Grant Schulert¹, Megan Quinlan-Waters¹, Alexandra Duell¹, Jennifer Huggins¹, Tiffany Nguyen², Cameron Sapp², Sumit Sharma³, Sunil Srivastava⁴ and Arjun Sood², ¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Cincinnati Eye Institute, Cincinnati, OH, ³Cole Eye Institute, Cleveland Clinic, Cleveland, OH, ⁴Cole Eye Institute, Cleveland Clinic, Cincinnati, OH
Background/Purpose: Pediatric uveitis is commonly associated with rheumatic disease and can lead to sight-threatening complications. Initial treatment are glucocorticoids and subsequently methotrexate (MTX) and TNF…
Abstract Number: 1106 • ACR Convergence 2022
Effect of Tocilizumab on Disease Activity in Patients with Active Polymyalgia Rheumatica on Glucocorticoid Therapy: A Randomized Clinical Trial
Valerie Devauchelle¹, Guillermo CARVAJAL ALEGRIA², Emmanuelle Dernis³, Christophe Richez⁴, Marie Truchetet⁵, Daniel Wendling⁶, ERIC TOUSSIROT⁷, aleth Perdriger⁸, jacques-eric gottenberg⁹, Renaud FELTEN¹⁰, Bruno Fautrel¹¹, laurent chiche¹², Pascal HILLIQUIN¹³, Catherine Le Henaff¹⁴, Benjamin Dervieux¹⁵, Guillaume Direz¹⁶, Isabelle Chary-Valckenaere¹⁷, Divi CORNEC¹⁸, Dewi Guellec¹⁹, Thierry MARHADOUR²⁰, Emmanule Nowak¹⁹ and Alain Saraux²¹, ¹Université de Bretagne Occidentale, Brest, France, ²CHRU de Tours, Tours, France, ³LE MANS general hospital, LE MANS, France, ⁴Université de Bordeaux, Bordeaux, France, ⁵Bordeaux University Hospital, Bordeaux, France, ⁶CHU, University Teaching Hospital, Besançon, France, ⁷CHU de Besançon, Besançon, France, ⁸Rennes University, Rennes, France, ⁹Strasbourg University Hospital, Strasbourg, France, ¹⁰Hôpitaux Universitaires de Strasbourg, Strasbourg, France, ¹¹Sorbonne University Paris, France and Pierre Louis Institute of Epidemiology and Public Health, Paris, France, Paris, France, ¹²hopital europeen, Marseille, France, ¹³Centre Hospitalier Sud-Francilien, Corbeil-Essonnes, France, ¹⁴Morlaix Hospital, Morlaix, France, ¹⁵Mulhouse Hospital, Mulhouse, France, ¹⁶Le Mans Hospital, Le Mans, France, ¹⁷Nancy University Hospital, Vandoeuvre, France, ¹⁸CHRU Brest, Brest, France, ¹⁹Brest University Hospital, Brest, France, ²⁰CHU Cavale Blanche, Brest, France, ²¹CHU Brest, Brest, France
Background/Purpose: Few treatments are available for patients with glucocorticoid-dependent polymyalgia rheumatica (PMR). Interleukin-6 antagonists deserve evaluation in active glucocorticoid-dependent PMR. Our objective was to compare…
Abstract Number: 1549 • ACR Convergence 2022
Toward Safer Glucocorticoid Therapy
Xingyu Pan¹, Qiongqiong Hou¹, Jiahui Xu¹, Yake Ma¹, Jiawen Li¹, Min Li¹, Jing Su¹, Xuerou Shi¹, William Bracken² and David Katz², ¹WuXi AppTec, Nantong, China, ²Sparrow Pharmaceuticals, Portland, OR
Background/Purpose: SPI-62 is a potent 11b-hydroxysteroid dehydrogenase type 1 (HSD-1) inhibitor entering Phase 2 development as adjunctive therapy to prednisolone in polymyalgia rheumatica, as well…
Abstract Number: 1584 • ACR Convergence 2022
Colchicine or Prednisone for the Treatment of Acute Calcium Pyrophosphate Deposition Arthritis: A Multicenter Randomized Controlled Trial
Tristan Pascart¹, Pierre Robinet², Sebastien Ottaviani³, Remi Leroy⁴, Nicolas Segaud⁵, Aurore Pacaud², Hélène Luraschi², Thibault Rabin², Agathe Grandjean², Xavier Deplanque⁶, Pierre Maciejasz⁶, Fabien Visade², Alexandre Mackowiak², Nicolas Baclet⁶, Antoine Lefebvre², Jean-François Budzik², Thomas Bardin⁷, Pascal Richette⁸, Laurène Norberciak², Vincent Ducoulombier² and Eric Houvenagel¹, ¹Groupement Hospitalier de l'Institut Catholique de Lille, Lomme, France, ²Hôpital Saint-Philibert, Lomme, France, ³Hopital Bichat-Claude Bernard, Paris, France, ⁴Centre Hospitalier de Dunkerque, Dunkerque, France, ⁵Centre Hospitalier d'Armentières, Armentières, France, ⁶Hôpital Saint-Vincent-de-Paul, Lille, France, ⁷Hôpital Lariboisiere, Paris, France, ⁸Department of Rheumatology, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Paris, France
Background/Purpose: Treatment of acute CPP arthritis mainly relies on expert opinion, as there are no trials that assessed the efficacy of anti-inflammatory drugs, despite the…
Abstract Number: 1795 • ACR Convergence 2022
Therapeutic Strategies for Patients with Chronic Manifestations of Calcium Pyrophosphate Deposition Disease
Julien Damart¹, Silvia Sirotti², Mariano Andrès³, Edoardo Cipolletta⁴, Georgios Filippou⁵, Davide Carboni⁶, Emilio Filippucci⁷, Pilar Diez⁸, Abhishek Abhishek⁹, Augustin Latourte¹⁰, Hang-Korng Ea¹¹, Sebastien Ottaviani¹², Jean-Guillaume Letarouilly¹³, Renaud Desbarbieux¹⁴, Sahara Graf¹, Laurène Norberciak¹, Pascal Richette¹⁵ and Tristan Pascart¹⁶, ¹Hôpital Saint-Philibert, Lomme, France, ²Università degli Studi di Milano, Milano, Italy, ³Dr Balmis Alicante General University Hospital-ISABIAL, Alicante, Spain, ⁴Polytechnic University of Marche, Ancona, Italy, ⁵Rheumatology Department, Luigi Sacco University Hospital, Siena, Italy, ⁶Luigi Sacco University, Milano, Italy, ⁷Polytechnic University of Marche, Rheumatology Unit, Department of Clinical and Molecular Sciences, "Carlo Urbani" Hospital, Jesi, Italy, ⁸Alicante University, Alicante, Spain, ⁹University of Nottingham, Nottingham, United Kingdom, ¹⁰Université de Paris, Paris, France, ¹¹Lariboisière Hospital, Paris, France, ¹²Hopital Bichat-Claude Bernard, Paris, France, ¹³CHU Lille, Lille, France, ¹⁴Ch Boulogne-sur-Mer, Boulogne-sur-Mer, France, ¹⁵Department of Rheumatology, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Paris, France, ¹⁶Groupement Hospitalier de l'Institut Catholique de Lille, Lomme, France
Background/Purpose: Calcium pyrophosphate deposition (CPPD) disease lacks recommendations on treatment strategies. This study reports on treatment modalities used in European tertiary hospitals for the management…
Abstract Number: 1837 • ACR Convergence 2022
Eales Disease and Vogt-Koyanagi-Harada Syndrome: Not Everything Is Anterior Uveitis in Rheumatology
Sonia Pastor Navarro¹, Olga Compán Fernández¹, Marta Ibáñez Martínez¹, Belén Miguel Ibáñez¹, Mireia Molina Pérez², Ángel Beltrán Mazo², Olga Martínez González¹, Carlos Montilla Morales¹, Ana Isabel Turrión Nieves¹, Susana Gómez Castro³ and Cristina Hidalgo Calleja¹, ¹Hospital Universitario de Salamanca, Salamanca, Spain, ²Hospital Universitario de Salamanca, Salamanca, Castilla y Leon, Spain, ³Hospital Universitario Salamanca, Salamanca, Spain
Background/Purpose: Ocular inflammatory involvement for being closely related to systemic autoimmune diseases is monitored and treated in our rheumatology visits. The most frequently studied by…
Abstract Number: 1843 • ACR Convergence 2022
Trends in the Cumulative Exposure to Corticosteroids in Polymyalgia Rheumatica (PMR) Patients: A Single Academic Center Experience
Vivekanand Tiwari¹, Vishnuteja Devalla², Emily Campbell¹ and William Rigby¹, ¹Dartmouth Hitchcock Medical Center, Lebanon, NH, ²Essential Health St. Joseph's-Brainerd Clinic, Brainerd, MN
Background/Purpose: Polymyalgia rheumatica (PMR) treatment is predominantly based on long-term corticosteroids, which results in significant corticosteroid-related toxicities. Studies1,2 have shown patients with PMR are exposed…
Abstract Number: 1909 • ACR Convergence 2022
Corticosteroids with or Without Hyaluronic Acid Injections in the Treatment of Trapeziometacarpal (TMC) Osteoarthritis : The Randomised Multicentre RHIZ’ART Trial Study Protocol
Grégoire Cormier¹, Amelie Denis², CHARLES LESKE³, Stephane Varin¹, Jerome Dimet⁴, Lucie Planche¹ and Benoit Le Goff⁵, ¹CHD Vendee, La Roche Sur Yon, France, ²CH Le Mans, Le Mans, France, ³Hospital, Cholet, France, ⁴CH Mont de Marsan, Mont de Marsan, France, ⁵CHU Nantes, Nantes, France
Background/Purpose: Trapeziometacarpal osteoarthritis is highly prevalent (affects 10 to 25% of people). Treatment modalities consist of non-pharmacological and pharmacological measures, including either corticosteroid or hyaluronic…
Abstract Number: 0134 • ACR Convergence 2022
Combination Treatment with Baricitinib and Pulse Steroids in Severe COVID19: A
Francesco Ferro¹, Elena Elefante², Italiano Nazzareno², Gaetano La Rocca³, Davide Schilirò², Michele Moretti², Roberto Mozzo⁴, De Simone Luigi⁴, Chiara Baldini⁵ and Marta Mosca², ¹Clinical and Experimental Medicine Department, Azienda Ospedaliero-Universitaria Pisana, Pisa, Pisa, Italy, ²University of Pisa, Pisa, Italy, ³University of Pisa, Rheumatology Unit, Palermo, Palermo, Italy, ⁴Anesthesiology & Intensive Care Unit/Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy, ⁵University of Pisa, Pisa, Pisa, Italy
Background/Purpose: Growing evidence from RCTs and real-life experiences has highlighted important similarities between severe COVID19 and rapidly progressive interstitial lung diseases (RP-ILD) occurring in connective…
Abstract Number: 2004 • ACR Convergence 2022
Which Route and Dose of Corticosteroids Is Most Effective in Inducing Remission in Early Rheumatoid Arthritis? A Systematic Literature Review and Meta-analysis
Laura Parker¹ and Nicola Gullick², ¹University of Warwick, Coventry, United Kingdom, ²University Hospital Coventry & Warwickshire; Warwick Medical School, University of Warwick, Coventry, United Kingdom
Background/Purpose: Current NICE guidance for rheumatoid arthritis (RA) states that glucocorticoids may be used for bridging therapy and to rapidly decrease inflammation in acute flares1.…
Abstract Number: 0353 • ACR Convergence 2022
Steroid-Induced Diabetes in Lupus Nephritis Patients: Classic Risk Factors or a Different Type of Diabetes?
Cristian Alejandro Dimas Ramírez¹, André Fortanell-Meza¹, Diego San Agustin-Morales¹, Eduardo Brenner Muslera², Juan Mejia-Vilet³, Paloma Almeda-Valdes⁴, Paola Vázquez Cárdenas⁵, F. Javier Merayo-Chalico⁶ and Ana Barrera-Vargas¹, ¹Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, Mexico, ²School of Medicine of Universidad Panamericana, Ciudad de México, Mexico, ³National Autonomous University of Mexico, Ciudad de México, Mexico, ⁴Department of Endocrinology and Metabolism, and the Research Unit of Metabolic Diseases. Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, Mexico, ⁵Hospital General Dr. Manuel Gea González, Ciudad de México, Mexico, ⁶Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirn", Ciudad de México, Mexico
Background/Purpose: Glucocorticoids are frequently employed in the treatment of systemic lupus erythematosus (SLE) patients and play a critical role in the induction therapy of lupus…
Abstract Number: 2005 • ACR Convergence 2022
Comparison of Treatment and Disease Activity in the Early Stage of Onset in Patients with Elderly-onset vs Younger-onset Rheumatoid Arthritis Using Data of National Database of Rheumatic Diseases in Japan (NinJa)
Toshihiro Matsui¹ and Shigeto Tohma², ¹NHO Sagamihara National Hospital, Kanagawa, Japan, ²National Hospital Organization Tokyo National Hospital, Dallas, TX
Background/Purpose: To clarify the current status and issues concerning treatment in the early stage of onset in patients with elderly-onset rheumatoid arthritis (RA) in Japan.Methods:…
Abstract Number: 0354 • ACR Convergence 2022
Clinical and Economic Characterization of Systemic Lupus Erythematosus Patients by Cumulative Corticosteroid Dose over 1 Year: Real-World Observation of Commercially Insured Adults in the United States
Sandra Sze-jung Wu¹, Allison Perry², Helen Varker³, Rich Bizier³, Liisa Palmer³ and Gary Bryant⁴, ¹AstraZeneca, Hockessin, DE, ²IBM Watson Health, New York, NY, ³Merative, Cambridge, MA, ⁴AstraZeneca, New Castle, DE
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex, heterogeneous disease associated with periods of flares. Identifying patients at risk of severe disease and associated resource…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].